Literature DB >> 19349226

Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo.

M Pievani1, P E Rasser, S Galluzzi, L Benussi, R Ghidoni, F Sabattoli, M Bonetti, G Binetti, P M Thompson, G B Frisoni.   

Abstract

Previous studies suggest that in Alzheimer's disease (AD) the Apolipoprotein E (APOE) epsilon4 allele is associated with greater vulnerability of medial temporal lobe structures. However, less is known about its effect on the whole cortical mantle. Here we aimed to identify APOE-related patterns of cortical atrophy in AD using an advanced computational anatomy technique. We studied 15 AD patients carriers (epsilon4+, age: 72+/-10 SD years, MMSE: 20+/-3 SD) and 14 non-carriers (epsilon4-, age: 69+/-9, MMSE: 20+/-5) of the epsilon4 allele and compared them to 29 age-and-sex matched controls (age: 70+/-9, MMSE: 28+/-1). Each subject underwent a clinical evaluation, a neuropsychological battery, and high-resolution MRI. UCLA's cortical pattern matching technique was used to identify regions of local cortical atrophy. epsilon4+ and epsilon4- patients showed similar performance on neuropsychological tests (p>.05, t-test). Diffuse cortical atrophy was detected for both epsilon4+ (p=.0001, permutation test) and epsilon4- patients (p=.0001, permutation test) relative to controls, and overall gray matter loss was about 15% in each patients group. Differences in gray matter loss between carriers and non-carriers mapped to the temporal cortex and right occipital pole (20% greater loss in carriers) and to the posterior cingulate, left orbitofrontal and dorsal fronto-parietal cortex (5-15% greater loss in non-carriers). APOE effect in AD was not significant (p>.74, ANOVA), but a significant APOE by region (temporal vs fronto-parietal cortex) interaction was detected (p=.002, ANOVA), in both early and late-onset patients (p<.05, ANOVA). We conclude that the epsilon4 allele modulates disease phenotype in AD, being associated with a pattern of differential temporal and fronto-parietal vulnerability.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19349226      PMCID: PMC2739903          DOI: 10.1016/j.neuroimage.2009.01.009

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  76 in total

1.  Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects.

Authors:  G E Smith; D L Bohac; S C Waring; E Kokmen; E G Tangalos; R J Ivnik; R C Petersen
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

2.  The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease.

Authors:  Y Stern; J Brandt; M Albert; D M Jacobs; X Liu; K Bell; K Marder; M Sano; S Albert; C Del-Castillo Castenada; F Bylsma; B Tycko; R Mayeux
Journal:  Ann Neurol       Date:  1997-05       Impact factor: 10.422

3.  Quantitative MR volumetry in Alzheimer's disease. Topographic markers and the effects of sex and education.

Authors:  D Kidron; S E Black; P Stanchev; B Buck; J P Szalai; J Parker; C Szekely; M J Bronskill
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

4.  The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics.

Authors:  M X Tang; Y Stern; K Marder; K Bell; B Gurland; R Lantigua; H Andrews; L Feng; B Tycko; R Mayeux
Journal:  JAMA       Date:  1998-03-11       Impact factor: 56.272

Review 5.  Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; S C Waring; E G Tangalos; G E Smith; R J Ivnik; S N Thibodeau; E Kokmen
Journal:  Ann Neurol       Date:  1998-03       Impact factor: 10.422

6.  The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery.

Authors:  G A Carlesimo; C Caltagirone; G Gainotti
Journal:  Eur Neurol       Date:  1996       Impact factor: 1.710

7.  Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes.

Authors:  M Lehtovirta; M P Laakso; H Soininen; S Helisalmi; A Mannermaa; E L Helkala; K Partanen; M Ryynänen; P Vainio; P Hartikainen
Journal:  Neuroscience       Date:  1995-07       Impact factor: 3.590

8.  Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease.

Authors:  Z Nagy; M M Esiri; K A Jobst; C Johnston; S Litchfield; E Sim; A D Smith
Journal:  Neuroscience       Date:  1995-12       Impact factor: 3.590

9.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein.

Authors:  T Polvikoski; R Sulkava; M Haltia; K Kainulainen; A Vuorio; A Verkkoniemi; L Niinistö; P Halonen; K Kontula
Journal:  N Engl J Med       Date:  1995-11-09       Impact factor: 91.245

10.  Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism.

Authors:  M Lehtovirta; H Soininen; S Helisalmi; A Mannermaa; E L Helkala; P Hartikainen; T Hänninen; M Ryynänen; P J Riekkinen
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

View more
  28 in total

Review 1.  Imaging genomics.

Authors:  Paul M Thompson; Nicholas G Martin; Margaret J Wright
Journal:  Curr Opin Neurol       Date:  2010-08       Impact factor: 5.710

2.  Dysexecutive versus amnestic Alzheimer disease subgroups: analysis of demographic, genetic, and vascular factors.

Authors:  Jesse Mez; Stephanie Cosentino; Adam M Brickman; Edward D Huey; Jennifer J Manly; Richard Mayeux
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Jul-Sep       Impact factor: 2.703

3.  Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease.

Authors:  David A Wolk; Bradford C Dickerson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans.

Authors:  Xue Hua; Derrek P Hibar; Suh Lee; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2010-08       Impact factor: 4.673

5.  The default mode network may be the key substrate of depressive symptom-related cognitive changes.

Authors:  Donald R Royall; Raymond F Palmer; Eric D Vidoni; Robyn A Honea
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

6.  The default mode network and related right hemisphere structures may be the key substrates of dementia.

Authors:  Donald R Royall; Raymond F Palmer; Eric D Vidoni; Robyn A Honea; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

7.  APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years.

Authors:  Joy L Taylor; Blake K Scanlon; Michelle Farrell; Beatriz Hernandez; Maheen M Adamson; J Wesson Ashford; Art Noda; Greer M Murphy; Michael W Weiner
Journal:  Neurobiol Aging       Date:  2014-05-15       Impact factor: 4.673

8.  Influence of brain-derived neurotrophic-factor and apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young adults.

Authors:  Tanja Richter-Schmidinger; Panagiotis Alexopoulos; Marco Horn; Sebastian Maus; Martin Reichel; Cosima Rhein; Piotr Lewczuk; Christos Sidiropoulos; Thomas Kneib; Robert Perneczky; Arnd Doerfler; Johannes Kornhuber
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

9.  Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease.

Authors:  Maria Vittoria Spampinato; Zoran Rumboldt; Robert J Hosker; Jacobo E Mintzer
Journal:  Radiology       Date:  2010-12-16       Impact factor: 11.105

10.  Neuroimaging predictors of brain amyloidosis in mild cognitive impairment.

Authors:  Duygu Tosun; Sarang Joshi; Michael W Weiner
Journal:  Ann Neurol       Date:  2013-09-10       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.